Introduction
============

Based on available epidemiological statistics, cancer has been one of the most common causes of morbidity and mortality around the world.[@b1-ott-9-2181] In the People's Republic of China, the overall cancer incidence rate and death rate were 235 and 114.3 (per 100,000 population) in 2013, respectively.[@b2-ott-9-2181] In the US, cancer is the second most common cause of death, and a total of 1,658,370 new cancer cases and 589,430 cancer deaths were expected to occur in 2015.[@b3-ott-9-2181] Cancer is a heterogeneous disease due to the involvement of complicated risk factors. There is an increase in the evidence that implies that predisposition to cancer is related to cytokines,[@b4-ott-9-2181] such as interleukin (IL).[@b5-ott-9-2181] Studies suggested that accumulation of genetic variants may be implicated in carcinogenesis.[@b6-ott-9-2181] Therefore, it would be of great importance to identify candidates for prevention and treatment of cancer.

IL-2 is an immunoregulatory cytokine produced by T helper type 1 cells when they are stimulated by mitogens, antigens, or major histocompatibility complexes on antigen-presenting cells.[@b7-ott-9-2181] It is involved in the chemical activity of T-cell-assisted immune responses and the enhancement of natural killer cell cytolytic process as a growth factor.[@b8-ott-9-2181]--[@b10-ott-9-2181] Pleiotropic reactions in the immune system occur when IL-2 acts as a protein, which regulates the pro- and anti-inflammatory processes.[@b11-ott-9-2181],[@b12-ott-9-2181] Medical scientists currently report that polymorphisms of *IL-2* gene have been associated with susceptibility to a range of inflammation malfunctions and cancer,[@b13-ott-9-2181] including gastric atrophy,[@b14-ott-9-2181] rheumatoid arthritis,[@b15-ott-9-2181] head and neck cancer,[@b16-ott-9-2181] gastric cancer (GC),[@b17-ott-9-2181] nasopharyngeal carcinoma,[@b18-ott-9-2181] non-Hodgkin lymphoma,[@b8-ott-9-2181] myelogenous leukemia,[@b19-ott-9-2181] hepatocellular carcinoma (HCC),[@b20-ott-9-2181] esophageal squamous cell carcinoma,[@b21-ott-9-2181] breast cancer,[@b6-ott-9-2181] and bladder cancer.[@b22-ott-9-2181] Clinical studies had revealed that both specific and nonspecific antitumor immune responses can be augmented by transfecting *IL-2* gene into tumor cells.[@b23-ott-9-2181],[@b24-ott-9-2181]

Human *IL-2* gene is encoded on chromosome 4q26 with well-characterized single-nucleotide polymorphisms, among which one (−330T/G, rs2069762) has been identified in the promoter region[@b15-ott-9-2181] and another (+114T/G, rs2069763) at position 114 from the initiation codon in the first exon.[@b25-ott-9-2181] Studies on *IL-2* gene polymorphisms demonstrated that they play significant roles in regulating the rate of inducible expression and secretion of *IL-2*.[@b26-ott-9-2181],[@b27-ott-9-2181] The association between single-nucleotide polymorphisms of *IL-2* gene and susceptibility to inflammation-based cancers, such as HCC and GC, has been reported in previously published case--control studies.[@b7-ott-9-2181],[@b8-ott-9-2181],[@b10-ott-9-2181],[@b13-ott-9-2181],[@b17-ott-9-2181],[@b19-ott-9-2181],[@b28-ott-9-2181]--[@b33-ott-9-2181] However, the findings were inconsistent and inconclusive because of the limited sample size. A quantitative synthesis to accumulate all currently available statistics from various studies may uncover evidences on the relationship between genetic polymorphisms and cancer susceptibility.

Although a meta-analysis of *IL-2* rs2069762 polymorphism and cancer risk has already been published recently,[@b34-ott-9-2181] there existed some drawbacks in that study. First, only one polymorphism of *IL-2* was identified, although other polymorphisms may also contribute to cancer susceptibility. Second, only ten publications were enrolled and one of them was ineligible.[@b35-ott-9-2181] The cases and controls of these studies were limited (3,060 cases and 3,435 controls). Third, it drew a conclusion that Hardy--Weinberg equilibrium (HWE) status did not affect the relationship of *IL-2* rs2069762 polymorphism and cancer susceptibility, which may not be reliable. Fourth, we found that there existed publication bias among included publications after careful calculation. To avoid the abovementioned limitations, we conducted the present meta-analysis aiming to further evaluate the association of *IL-2* rs2069763 and rs2069762 polymorphisms with overall cancer susceptibility in 12 publications with 1,556 cases/2,405 controls and 4,054 cases/5,405 controls, respectively.

Materials and methods
=====================

Search strategy
---------------

We conducted a comprehensive collection research by retrieving PubMed, Web of Science, and Google Scholar databases. The keywords of retrieve were ("*IL-2*" OR "interleukin-2") AND ("polymorphism" OR "variant" OR "mutation") in combination with ("cancer" OR "tumor" OR "carcinoma" OR "leukemia") without language restriction. The research design was limited to humans. All eligible studies were inspected carefully.

Inclusion and exclusion criteria
--------------------------------

Only those articles satisfying the following criteria were included: 1) studies that assessed the association between *IL-2* polymorphisms and cancer susceptibility; 2) studies that were case--control or cohort in design; and 3) studies from which detailed genotype frequencies of cases and controls could be obtained directly or calculated from the available data. We excluded studies when they were 1) not case--control study, such as reviews, case reports, and comments; 2) articles without sufficient data of *IL-2* genotype; and 3) duplicate data.

Quality assessment
------------------

The quality of the enrolled studies was examined independently by Xiuxiu Tan and Junjie Huang referring to the Newcastle--Ottawa scale,[@b36-ott-9-2181] which evaluates the quality of nonrandomized studies by the selection of participants, comparability of groups, and exposure assessment. Disagreement was settled as described previously.

Data extraction
---------------

The details of each satisfied study were carefully filtered by three independent investigators (Meng Zhang, Xiuxiu Tan, and Junjie Huang). Any disagreements were resolved by discussion until a consensus was reached. The name of first author, the year of publication, ethnicity, source of control, genotyping method, the number of cases and controls, and the *P*-value of HWE in control groups were collected from each study.

Statistical analysis
--------------------

The STATA 12.0 software program (Stata Corp, College Station, TX, USA) was used to perform this meta-analysis. The odds ratio (OR) and 95% confidence interval (CI) were calculated to assess the association between *IL-2* gene polymorphisms and cancer susceptibility. Five different ORs were used to compute: allele contrast model (G vs T), dominant model (GG + GT vs TT), recessive model (GG vs GT + TT), heterozygote comparison (GT vs TT), and homozygote comparison (GG vs TT) (TT, homozygotes for the common allele; GT, heterozygotes; GG, homozygotes). We adopted chi-square test-based *Q* statistic test to assess the heterogeneity within the case--control studies. When the *Q*-test (*P*\>0.1) shows homogeneity across studies, we should choose the fixed effects model;[@b37-ott-9-2181] otherwise, the random effects model should be selected.[@b38-ott-9-2181] In addition, the effect of heterogeneity was quantified by the *I*^2^ value (*I*^2^\<25%: no heterogeneity; *I*^2^=25%--50%: moderate heterogeneity; *I*^2^=50%--75%: high heterogeneity; and *I*^2^\>75%: extreme high heterogeneity).[@b39-ott-9-2181] We also measured the HWE of control groups. We applied stratification analyses on cancer type and ethnicity. Sensibility analysis was performed to assess the stability of the results by deleting one single case--control study each time from enrolled pooled data. In the end, the potential publication bias was evaluated by Begg's funnel plot and Egger's regression test. *P*\<0.05 was considered as statistically significant.

Result
======

Included studies' identification and characteristics
----------------------------------------------------

As shown in [Figure 1](#f1-ott-9-2181){ref-type="fig"}, the literature research identified a total of 354 related publications. After reading the title and abstract, we reserved 18 articles concerning the association between *IL-2* polymorphisms and cancer susceptibility. Additional six publications were excluded since there were no data for *IL-2* polymorphisms or were duplicates or were about other *IL* polymorphisms. Finally, a total of 12 publications were enrolled. For *IL-2* rs2069763 polymorphism, a total of five publications with six case--control studies comprising 1,556 cases and 2,405 controls were enrolled, while 12 publications with 15 case--control studies comprising 4,045 cases and 5,404 controls were included for rs2069762 polymorphism.

As shown in [Table 1](#t1-ott-9-2181){ref-type="table"}, for the six studies of *IL-2* rs2069763 polymorphism, three were hospital-based designs and the others were population-based designs. In addition, three studies conformed to HWE while others did not.[@b31-ott-9-2181],[@b32-ott-9-2181] As for *IL-2* rs2069762 polymorphism, four studies were population based and eleven were hospital based. Six conformed to HWE while others did not.[@b7-ott-9-2181],[@b8-ott-9-2181],[@b13-ott-9-2181],[@b17-ott-9-2181],[@b28-ott-9-2181],[@b30-ott-9-2181],[@b31-ott-9-2181] When sorted by cancer type, there were two HCC studies, five GC studies, and eight other studies. In terms of the ethnic populations in these studies, nine were from the People's Republic of China and six were non-Chinese.

Results of pooled meta-analysis
-------------------------------

[Tables 2](#t2-ott-9-2181){ref-type="table"} and [3](#t3-ott-9-2181){ref-type="table"} presented the results of meta-analysis, it demonstrated that no significant association between *IL-2* rs2069763 and cancer susceptibility was identified ([Table 2](#t2-ott-9-2181){ref-type="table"}, homozygous: OR =1.039, 95% CI =0.862--1.252; heterozygous: OR =1.046, 95% CI =0.888--1.232; recessive: 0.972, 95% CI =0.835--1.133; dominant: OR =1.060, 95% CI =0.912--1.230; and allele comparing: OR =0.983, 95% CI =0.895--1.079), whereas an increased susceptibility between cancer and rs2069762 polymorphism was uncovered ([Table 3](#t3-ott-9-2181){ref-type="table"}, G vs T: OR =1.268, 95% CI =1.113--1.445; GG vs TT: OR =1.801, 95% CI =1.289--2.516, [Figure 2](#f2-ott-9-2181){ref-type="fig"}; GT vs TT: OR =1.250, 95% CI =1.061--1.473; GG + GT vs TT: OR =1.329, 95% CI =1.118--1.579; GG vs GT + TT: OR =1.536, 95% CI =1.162--2.030).

Result of subgroup
------------------

[Tables 2](#t2-ott-9-2181){ref-type="table"} and [3](#t3-ott-9-2181){ref-type="table"} also show the outcomes of subgroup analysis. The data in [Table 2](#t2-ott-9-2181){ref-type="table"} suggested that rs2069763 polymorphism of *IL-2* has no significant association with cancer susceptibility in the subgroups sorted by either source of controls or *P*~HWE~. However, as for rs2069762 polymorphism ([Table 3](#t3-ott-9-2181){ref-type="table"}), it demonstrated an increased susceptibility to cancer in the hospital-based studies (G vs T: OR =1.286, 95% CI =1.095--1.511; GG vs TT: OR =1.950, 95% CI =1.279--2.971; GT vs TT: OR =1.220, 95% CI =1.017--1.464; GG + GT vs TT: OR =1.310, 95% CI =1.074--1.599, [Figure 3](#f3-ott-9-2181){ref-type="fig"}; GG vs GT + TT: OR =1.683, 95% CI =1.180--2.400) and the *P*~HWE~\<0.5 group (G vs T: OR =1.341, 95% CI =1.151--1.561 and GG vs TT: OR =2.156, 95% CI =1.326--3.507, [Figure 4](#f4-ott-9-2181){ref-type="fig"}; GT vs TT: OR =1.337, 95% CI =1.109--1.613; GG + GT vs TT: OR =1.421, 95% CI =1.175--1.720; and GG vs GT + TT: OR =1.827, 95% CI =1.173--2.845). In the subgroup meta-analysis by ethnicity, the rs2069762 polymorphism was observed with positive association with cancer susceptibility among both Chinese and non-Chinese. Specifically, the analysis indicated that non-Chinese population suffered more risk from this polymorphism (G vs T: OR =1.652, 95% CI =1.302--2.097; GG vs TT: OR =4.264, 95% CI =1.506--12.069, [Figure 5](#f5-ott-9-2181){ref-type="fig"}; GT vs TT: OR =1.525, 95% CI =1.089--2.136; GG + GT vs TT: OR =1.647, 95% CI =1.252--2.166; and GG vs GT + TT: OR =3.341, 95% CI =1.218--9.161) than Chinese (G vs T: OR =1.162, 95% CI =1.013--1.332; GG vs TT: OR =1.438, 95% CI =1.058--1.954, [Figure 5](#f5-ott-9-2181){ref-type="fig"}; GT vs TT: OR =1.180, 95% CI =0.982--1.418; GG + GT vs TT: OR =1.223, 95% CI =1.003--1.490; and GG vs GT + TT: OR =1.302, 95% CI =1.040--1.629). However, no relationship was identified between the rs2069762 polymorphism of *IL-2* and cancer susceptibility within a certain type of cancer.

Sensitivity analysis and publication bias
-----------------------------------------

We executed a sensitivity analysis to assess the influence of separate study on the pooled ORs by excluding one single study each time and a negative result was achieved ([Figure 6](#f6-ott-9-2181){ref-type="fig"}). We detected publication bias through Begg's funnel plot and Egger's test. As shown in [Figure 7](#f7-ott-9-2181){ref-type="fig"}, significant publications bias was revealed for rs2069762 (Egger's test *P*=0.005), while no obvious bias was identified for rs2069763 (Egger's test *P*=0.146). Therefore, trim and fill method was conducted for rs2069762 to further evaluate the publication bias. As shown in [Figure 8](#f8-ott-9-2181){ref-type="fig"}, four theoretical studies were added and no significant difference was obtained (*P*\<0.05), proving the stability of our results. The quality of enrolled studies is presented in [Table 4](#t4-ott-9-2181){ref-type="table"}.

Discussion
==========

The association between *IL-2* gene polymorphisms and susceptibility to various cancers are widely discussed these days. Unfortunately, the results are inconsistent and inconclusive. A recent meta-analysis concerning the association between rs2069762 polymorphism of *IL-2* and cancer susceptibility was published, and their results suggested that *IL-2* rs2069762 polymorphism was significantly associated with cancer risk. However, several limitations should be noted for this study. First, the investigators only enrolled ten publications for rs2069762 polymorphism, including ten case--controls comprising of 3,060 cases and 3,435 controls.[@b34-ott-9-2181] However, one unqualified publication was enrolled,[@b35-ott-9-2181] which adopted samples instead of blood tissues, distinguishing it from other enrolled studies and potentially contributing to bias. In the present work, we excluded this publication and added another three publications. We detected a total of 12 publications, including 15 case--controls comprising of 4,045 cases and 5,404 controls. Second, we also enrolled another *IL-2* polymorphism (rs2069763), with five publications containing six case--control studies comprising of 1,556 cases and 2,405 controls, which broadened the scope of analysis. Third, the subgroup analysis sorted by *P*~HWE~ in previous meta-analysis showed that *P*~HWE~ status did not affect the correlation between *IL-2*-330T/G polymorphism and cancer susceptibility. Nevertheless, in our study, a significant association was found between *P*~HWE~\<0.05 group and cancer susceptibility, while no association was identified between *P*~HWE~≥0.05 group and cancer susceptibility. Our work demonstrated that the *P*~HWE~ status had a great effect on the pooled ORs. Although no publication bias was found in the previous study, when we excluded the ineligible study from the pooled data and assessed again, significant publication bias was uncovered.[@b35-ott-9-2181]

Although we have conducted a comprehensive retrieve and revised the disadvantages of the previous study, there are still several limitations that should be noted. First, since cancer is considered a multifactorial disease with interactions between multiple environmental exposures and individual genetic backgrounds, we failed to analyze the gene--gene and gene--environment effects in this study due to insufficient data. Second, most of the included studies were conducted in the Asian and Caucasian populations, thus, the conclusions may barely adapt to these populations. Further studies within different ethnic populations such as Africans and Latinos are warranted. Last but not least, the limited number of studies included in the meta-analysis may result in low statistical power to obtain an ideal precision of the pooled estimates.

Conclusion
==========

In conclusion, our meta-analysis suggested that there is no association between rs2069763 polymorphism of *IL-2* and cancer susceptibility, whereas an increased susceptibility to cancer was uncovered for rs2069762 polymorphism. Further well-designed studies are still warranted to further exclude the influence of *P*~HWE~\<0.05 and hospital-based groups on cancer susceptibility.
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![OR estimates with the corresponding 95% CI for the association of *IL-2* rs2069762 polymorphism with overall cancer risk (GG vs TT); the sizes of the squares represent the weighting of included studies.\
**Note:** Weights are from random effect analysis.\
**Abbreviations:** OR, odds ratio; *IL-2*, *interleukin-2*.](ott-9-2181Fig2){#f2-ott-9-2181}

![OR estimates with the corresponding 95% CI for the association of *IL-2* rs2069762 polymorphism with overall cancer risk (GG + GT vs TT) in the subgroups sorted by the source of control; the sizes of the squares represent the weighting of included studies.\
**Note:** Weights are from random effect analysis.\
**Abbreviations:** OR, odds ratio; *IL-2*, *interleukin-2*; HB, hospital-based; PB, population-based.](ott-9-2181Fig3){#f3-ott-9-2181}

![OR estimates with the corresponding 95% CI for the association of *IL-2* rs2069762 polymorphism with overall cancer risk (GG vs TT) in the subgroups of *P*~HWE~\<0.5; the sizes of the squares represent the weighting of included studies.\
**Note:** Weights are from random effect analysis.\
**Abbreviations:** OR, odds ratio; *IL-2*, *interleukin-2*; Y, *P*~HWE~\>0.05; N, *P*~HWE~≤0.05.](ott-9-2181Fig4){#f4-ott-9-2181}

![OR estimates with the corresponding 95% CI for the association of *IL-2* rs2069762 polymorphism with overall cancer risk (GG vs TT) in the subgroups sorted by ethnic lines; the sizes of the squares represent the weighting of included studies.\
**Note:** Weights are from random effect analysis.\
**Abbreviations:** OR, odds ratio; *IL-2*, *interleukin-2*.](ott-9-2181Fig5){#f5-ott-9-2181}

![Sensibility analysis in studies of the association between the *IL-2* rs2069762 polymorphism and cancer susceptibility assessed by deleting one single case--control study at each time from inclusion pooled.\
**Abbreviation:** *IL-2*, *interleukin-2*.](ott-9-2181Fig6){#f6-ott-9-2181}

![Publication bias in studies of the association between the *IL-2* rs2069762 polymorphism and cancer susceptibility assessed by Begg's funnel plot and Egger's test.\
**Abbreviations:** Log(OR), the natural logarithm of the odds ratio; *IL-2*, *interleukin-2*; SE, standard error.](ott-9-2181Fig7){#f7-ott-9-2181}

![Publication bias in studies of the association between the *IL-2* rs2069762 polymorphism and cancer susceptibility after the trim and fill method was assessed by Begg's funnel plot and Egger's test.\
**Abbreviation:** SE, standard error.](ott-9-2181Fig8){#f8-ott-9-2181}

###### 

Characteristics of eligible studies in this meta-analysis

  SNP         Reference                           Year   Ethnicity   Genotyping method   Source of control   Cancer type      Case   Control                                   
  ----------- ----------------------------------- ------ ----------- ------------------- ------------------- ---------------- ------ --------- ----- ----- ----- ----- ------- ---
  rs2069763   Peng et al[@b32-ott-9-2181]         2014   Chinese     PCR-RFLP            HB                  HCC              21     56        30    78    117   92    0.002   N
              Wei et al[@b10-ott-9-2181]          2010   Chinese     PCR-RFLP            HB                  NP               40     93        47    57    99    44    0.935   Y
              Song et al[@b8-ott-9-2181]          2012   Chinese     PCR-RFLP            HB                  NHL              128    220       90    138   240   104   0.985   Y
              Savage et al[@b31-ott-9-2181]       2004   Chinese     PCR                 PB                  GCC              14     35        33    80    148   149   0.002   N
              Savage et al[@b31-ott-9-2181]       2004   Chinese     PCR                 PB                  ESCC             26     41        44    80    148   149   0.002   N
              Hu et al[@b28-ott-9-2181]           2013   Chinese     PCR                 HB                  Breast cancer    187    320       131   197   342   143   0.809   Y
  rs2069762   Bei et al[@b33-ott-9-2181]          2014   Chinese     PCR                 HB                  HCC              292    333       95    311   373   100   0.469   Y
              Peng et al[@b32-ott-9-2181]         2014   Chinese     PCR-RFLP            HB                  HCC              47     54        6     101   158   28    0.003   N
              Wei et al[@b10-ott-9-2181]          2010   Chinese     PCR-RFLP            HB                  NP               46     106       28    81    102   17    0.054   Y
              Song et al[@b29-ott-9-2181]         2012   Korean      GOPA                HB                  CL               7      11        5     87    54    7     0.706   Y
              Song et al[@b8-ott-9-2181]          2012   Chinese     PCR-RFLP            HB                  NHL              136    246       56    193   250   39    0       N
              Amirzargar et al[@b13-ott-9-2181]   2005   Iranian     PCR-SSP             PB                  CML              4      24        2     16    23    1     0.032   N
              Berković et al[@b30-ott-9-2181]     2010   Caucasian   PCR                 HB                  GEP-NET          46     41        14    83    63    4     0.047   N
              Berković et al[@b30-ott-9-2181]     2010   Caucasian   PCR                 HB                  PET              21     17        8     83    63    4     0.047   N
              Berković et al[@b30-ott-9-2181]     2010   Caucasian   PCR                 HB                  GI-NET           25     24        6     83    63    4     0.047   N
              Savage et al[@b31-ott-9-2181]       2004   Chinese     PCR                 PB                  GCC              20     47        16    109   174   96    0.116   Y
              Savage et al[@b31-ott-9-2181]       2004   Chinese     PCR                 PB                  ESCC             33     43        35    109   174   96    0.116   Y
              Hu et al[@b28-ott-9-2181]           2013   Chinese     PCR                 HB                  Breast cancer    192    357       89    275   351   56    0       N
              Shin et al[@b17-ott-9-2181]         2008   Korean      PCR                 HB                  Gastric cancer   79     35        8     72    16    12    0       N
              Shen et al[@b7-ott-9-2181]          2012   Chinese     PCR                 PB                  Bladder cancer   109    205       51    157   200   33    0.005   N
              Wu et al[@b19-ott-9-2181]           2009   Chinese     PCR                 HB                  Gastric cancer   491    441       94    516   480   87    0.091   Y

**Notes:** *P*~HWE~\>0.05, polymorphisms conformed to HWE in the control group and *P*~HWE~≤0.05, polymorphisms did not conform to HWE in the control group.

**Abbreviations:** SNP, single-nucleotide polymorphism; HWE, Hardy--Weinberg equilibrium; Y, *P*~HWE~\>0.05; N, *P*~HWE~≤0.05; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; HB, hospital based; HCC, hepatocellular carcinoma; NP, nasopharyngeal; NHL, non-Hodgkin lymphoma; PCR, polymerase chain reaction; PB, population based; GCC, gastric cardia cancer; ESCC, esophageal squamous cell carcinoma; Tag, Tagzilla algorithm; CL, childhood lymphoma; PCR-SSP, polymerase chain reaction--sequence-specific primers; CML, chronic myelogenous leukemia; GEP-NET, gastroenteropancreatic neuroendocrine tumor; PET, pancreatic endocrine tumor; GI-NET, gastrointestinal neuroendocrine tumor; GOPA, GoldenGate™ oligonucleotide pool assay.

###### 

Results of meta-analysis for rs2069763 polymorphism in *IL-2* and cancer susceptibility

  Variables (rs2069763)   Case/control   OR (95% CI)             *P*-value[a](#tfn4-ott-9-2181){ref-type="table-fn"}   *I*^2^ (%)   OR (95% CI)             *P*-value[a](#tfn4-ott-9-2181){ref-type="table-fn"}   *I*^2^ (%)   OR (95% CI)            *P*-value[a](#tfn4-ott-9-2181){ref-type="table-fn"}   *I*^2^ (%)
  ----------------------- -------------- ----------------------- ----------------------------------------------------- ------------ ----------------------- ----------------------------------------------------- ------------ ---------------------- ----------------------------------------------------- ------------
                                         **G vs T**                                                                                 **GG vs TT**                                                                               **GT vs TT**                                                                 
  Total                   1,556/2,405    0.983 (0.895--1.079)    0.748                                                 0.0          1.039 (0.862--1.252)    0.701                                                 0.0          1.046 (0.888--1.232)   0.803                                                 0.0
  Source of control                                                                                                                                                                                                                                                                                         
   HB                     1,363/1,651    0.984 (0.888--1.090)    0.511                                                 0.0          1.039 (0.844--1.278)    0.484                                                 0.0          1.060 (0.881--1.275)   0.551                                                 0.0
   PB                     193/754        0.980 (0.780--1.231)    0.538                                                 0.0          1.040 (0.677--1.598)    0.460                                                 0.0          0.995 (0.697--1.420)   0.723                                                 0.0
  HWE                                                                                                                                                                                                                                                                                                       
   Y                      1,256/1,364    0.990 (0.888--1.104)    0.336                                                 8.3          0.981 (0.788--1.222)    0.334                                                 8.9          1.010 (0.829--1.232)   0.803                                                 0.0
   N                      300/1,041      0.963 (0.801--1.159)    0.800                                                 0.0          0.916 (0.642--1.308)    0.704                                                 0.0          1.128 (0.842--1.511)   0.453                                                 0.0
                                         **GG** + **GT vs TT**                                                                      **GG vs GT** + **TT**                                                                                                                                                   
  Total                   1,556/2,405    1.060 (0.912--1.230)    0.440                                                 0.0          0.972 (0.835--1.133)    0.962                                                 0.0                                                                                       
  Source of control                                                                                                                                                                                                                                                                                         
   HB                     1,363/1,651    1.064 (0.905--1.250)    0.277                                                 22.2         0.963 (0.807--1.148)    0.820                                                 0.0                                                                                       
   PB                     193/754        1.036 (0.701--1.532)    0.334                                                 0.0          1.002 (0.737--1.363)    0.838                                                 0.0                                                                                       
  HWE                                                                                                                                                                                                                                                                                                       
   Y                      1,256/1,364    1.024 (0.864--1.214)    0.377                                                 0.0          0.993 (0.822--1.199)    0.962                                                 0.0                                                                                       
   N                      300/1,041      1.188 (0.866--1.632)    0.321                                                 12.0         0.935 (0.722--1.212)    0.708                                                 0.0                                                                                       

**Notes:** *I*^2^: 0--25, means no heterogeneity; 25--50, means modest heterogeneity; and \>50, means high heterogeneity; Y: polymorphisms conformed to HWE in the control group; N: polymorphisms did not conform to in the control group.

*P*-value of Q-test for heterogeneity test.

Statistically significant (*P*\<0.05). Five different ORs were used to compute: allele contrast model (G vs T), dominant model (GG + GT vs TT), recessive model (GG vs GT + TT), heterozygote comparison (GT vs TT), and homozygote comparison (GG vs TT) (TT, homozygotes for the common allele; GT, heterozygotes; GG, homozygotes).

**Abbreviations:** OR, odds ratio; HB, hospital based; PB, population based; HWE, Hardy--Weinberg equilibrium; Y, *P*~HWE~\>0.05; N, *P*~HWE~≤0.05.

###### 

Results of meta-analysis for rs2069762 polymorphism in *IL-2* and cancer susceptibility

  Variables (rs2069762)   Case/control   OR (95% CI)                                                           *P*-value[a](#tfn8-ott-9-2181){ref-type="table-fn"}   *I*^2^ (%)   OR (95% CI)                                                               *P*-value[a](#tfn8-ott-9-2181){ref-type="table-fn"}   *I*^2^   OR (95% CI)                                                           *P*-value[a](#tfn8-ott-9-2181){ref-type="table-fn"}   *I*^2^
  ----------------------- -------------- --------------------------------------------------------------------- ----------------------------------------------------- ------------ ------------------------------------------------------------------------- ----------------------------------------------------- -------- --------------------------------------------------------------------- ----------------------------------------------------- --------
                                         **G vs T**                                                                                                                               **GG vs TT**                                                                                                                             **GT vs TT**                                                                                                                
  Total                   4,045/5,404    **1.268 (1.113--1.445)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.000                                                 70.6         **1.801 (1.289--2.516)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}       0.000                                                 74.9     **1.250 (1.061--1.473)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.002                                                 58.7
  Cancer type                                                                                                                                                                                                                                                                                                                                                                                                                                          
   GC                     1,387/1,862    1.169 (0.948--1.442)                                                  0.087                                                 50.8         1.549 (0.783--3.064)                                                      0.005                                                 72.9     1.193 (0.923--1.541)                                                  0.191                                                 34.6
   HCC                    827/1,071      0.899 (0.694--1.165)                                                  0.138                                                 54.5         0.778 (0.375--1.612)                                                      0.123                                                 58.0     0.908 (0.745--1.105)                                                  0.323                                                 0.0
  Source of control                                                                                                                                                                                                                                                                                                                                                                                                                                    
   HB                     3,456/4,216    **1.286 (1.095--1.511)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.000                                                 76.0         **1.950 (1.279**--**2.971)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.000                                                 79.7     **1.220 (1.017--1.464)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.005                                                 60.0
   PB                     589/1,188      1.232 (0.988--1.537)                                                  0.145                                                 44.5         1.493 (0.872--2.556)                                                      0.092                                                 53.4     1.383 (0.896--2.136)                                                  0.063                                                 58.9
  HWE                                                                                                                                                                                                                                                                                                                                                                                                                                                  
   Y                      2,143/2,973    1.172 (0.971--1.415)                                                  0.003                                                 71.6         1.410 (0.953--2.085)                                                      0.007                                                 68.5     1.144 (0.897--1.459)                                                  0.122                                                 42.5
   N                      1,902/2,431    **1.341 (1.151--1.561)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.030                                                 53.0         **2.156 (1.326--3.507)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}       0.001                                                 70.1     **1.337 (1.109--1.613)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.127                                                 36.4
  Ethnicity                                                                                                                                                                                                                                                                                                                                                                                                                                            
   Chinese                3,668/4,666    **1.162 (1.013--1.332)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.000                                                 74.2         **1.438 (1.058--1.954)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}       0.000                                                 72.1     1.180 (0.982--1.418)                                                  0.002                                                 67.7
   Non-Chinese            377/738        **1.652 (1.302--2.097)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.254                                                 23.9         **4.264 (1.506--12.069)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}      0.003                                                 72.3     **1.525 (1.089--2.136)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.278                                                 20.7
                                         **GG** + **GT vs TT**                                                                                                                    **GG vs GT** + **TT**                                                                                                                                                                                                                                                
  Total                   4,045/5,404    **1.329 (1.118--1.579)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.000                                                 66.4         **1.536 (1.162--2.030)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}       0.000                                                 68.8                                                                                                                                 
  Cancer type                                                                                                                                                                                                                                                                                                                                                                                                                                          
   GC                     1,387/1,862    1.140 (0.948--1.370)                                                  0.334                                                 12.6         1.386 (0.698--2.750)                                                      0.002                                                 77.1                                                                                                                                 
   HCC                    827/1,071      0.871 (0.647--1.173)                                                  0.194                                                 40.8         0.879 (0.506--1.525)                                                      0.192                                                 41.2                                                                                                                                 
  Source of control                                                                                                                                                                                                                                                                                                                                                                                                                                    
   HB                     3,456/4,216    **1.310 (1.074--1.599)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.000                                                 70.2         **1.683 (1.180--2.400)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}       0.000                                                 74.0                                                                                                                                 
   PB                     589/1,188      1.408 (0.954--2.079)                                                  0.085                                                 54.7         1.263 (0.802--1.990)                                                      0.104                                                 51.2                                                                                                                                 
  HWE                                                                                                                                                                                                                                                                                                                                                                                                                                                  
   Y                      2,143/2,973    1.207 (0.936--1.557)                                                  0.009                                                 67.3         1.260 (0.922--1.721)                                                      0.029                                                 59.9                                                                                                                                 
   N                      1,902/2,431    **1.421 (1.175--1.720)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.078                                                 43.4         **1.827 (1.173--2.845)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}       0.002                                                 67.5                                                                                                                                 
  Ethnicity                                                                                                                                                                                                                                                                                                                                                                                                                                            
   Chinese                3,668/4,666    **1.223 (1.003--1.490)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.000                                                 74.7         **1.302 (1.040--1.629)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}       0.020                                                 56.1                                                                                                                                 
   Non-Chinese            377/738        **1.647 (1.252--2.166)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}   0.406                                                 1.5          **3.341 (1.218--9.161)**[\*](#tfn9-ott-9-2181){ref-type="table-fn"}       0.002                                                 72.9                                                                                                                                 

**Notes:** *I*^2^: 0--25, means no heterogeneity; 25--50, means modest heterogeneity; and \>50, means high heterogeneity; Y: polymorphisms conformed to HWE in the control group; N: polymorphisms did not conform to HWE in the control group.

*P*-value of *Q*-test for heterogeneity test.

Statistically significant (*P*\<0.05), boldface values represent statistical significance. Five different ORs were used to compute: allele contrast model (G vs T), dominant model (GG + GT vs TT), recessive model (GG vs GT + TT), heterozygote comparison (GT vs TT), and homozygote comparison (GG vs TT) (TT, homozygotes for the common allele; GT, heterozygotes; GG, homozygotes).

**Abbreviations:** OR, odds ratio; GC, gastric cancer; HCC, hepatocellular carcinoma; HB, hospital-based cancer type; PB, population based cancer type; HWE, Hardy--Weinberg equilibrium; Y, *P*~HWE~\>0.05; N, *P*~HWE~≤0.05.

###### 

Methodological quality of the included studies according to the Newcastle--Ottawa scale

  Author                                         Ethnicity   Adequacy of case definition   Representativeness of the cases   Selection of controls   Definition of controls   Comparability cases/controls   Ascertainment of exposure   Same method of ascertainment   Nonresponse rate
  ---------------------------------------------- ----------- ----------------------------- --------------------------------- ----------------------- ------------------------ ------------------------------ --------------------------- ------------------------------ ------------------
  Peng et al[@b32-ott-9-2181]                    Chinese     \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Wei et al[@b10-ott-9-2181]                     Chinese     \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Song et al[@b8-ott-9-2181]                     Chinese     \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Savage et al[@b31-ott-9-2181]                  Chinese     \*                            \*                                \*                      NA                       \*\*                           \*                          \*                             \*
  Hu et al[@b28-ott-9-2181]                      Chinese     \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Bei et al[@b33-ott-9-2181]                     Chinese     \*                            \*                                NA                      NA                       \*\*                           \*                          \*                             \*
  Peng et al[@b32-ott-9-2181]                    Chinese     \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Wei et al[@b10-ott-9-2181]                     Chinese     \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Nan et al                                      Korean      \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Song et al[@b8-ott-9-2181],[@b29-ott-9-2181]   Chinese     \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Amirzargar et al[@b13-ott-9-2181]              Iranian     \*                            \*                                \*                      \*                       \*\*                           \*                          \*                             \*
  Berković et al[@b30-ott-9-2181]                Caucasian   \*                            \*                                NA                      NA                       \*\*                           \*                          \*                             \*
  Savage et al[@b31-ott-9-2181]                  Chinese     \*                            \*                                \*                      NA                       \*\*                           \*                          \*                             \*
  Hu et al[@b28-ott-9-2181]                      Chinese     \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Shin et al[@b17-ott-9-2181]                    Korean      \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*
  Shen et al[@b7-ott-9-2181]                     Chinese     \*                            \*                                \*                      \*                       \*\*                           \*                          \*                             \*
  Wu et al[@b19-ott-9-2181]                      Chinese     \*                            \*                                NA                      \*                       \*\*                           \*                          \*                             \*

**Notes:** This table identifies "high"-quality choices with a "star." A study can be awarded a maximum of one star for each numbered item within the selection and exposure categories. A maximum of two stars can be given for comparability.

**Abbreviation:** NA, not applicable.

[^1]: These authors contributed equally to this work
